CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page . Jefferies Global Healthcare Conference in London Tuesday, Nov. 17, 2026 at 10:30 A.M. GMT (5:30 A.M. ET) 9th Annual Evercore Healthcare Conference Tuesday, Dec. 1, 2026 at 8:

Pivotal trial data to be featured in an oral presentation during AAGL Scientific Sessions; results published in Fertility and Sterility with accompanying independent editorial. BURLINGTON, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a commercial-stage women’s health company focused on uterine health, today announced its participation in the AAGL 55th Global Congress on Minimally Invasive Gynecologic Surgery (MIGS), taking place Nov. 13-16, 2026, at the Hynes Convention Center in Boston. At the meeting

Studies in epidermodysplasia verruciformis and Peutz-Jeghers syndrome will measure outcomes for patients whose care rests on expert opinion rather than cohort evidence WARREN, N.J. , Nov. 12, 2026 /PRNewswire/ -- Regal Intel, Inc., a 501(c)(3) nonprofit research organization, has received two seed grants to measure what happens to patients with epidermodysplasia verruciformis (EV) and Peutz-Jeghers syndrome (PJS) under surveillance guidelines that have never been tested against outcomes. The a

PALO ALTO, Calif. and SUZHOU, China , Nov. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular, and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IAR177 as a poster in ACR Convergence 2026 held in Orlando, Florida. By simultaneously targeti

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, bef

iStock, Love Employee Less than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic. PharmaLogic has struck a deal to buy a radiopharmaceutical contract development and manufacturing organization (CDMO) and production plant from Lantheus. Lantheus acquired the CDMO and Springfield, New Jersey, production facility last year when it bought Evergreen Theragnostics for $250 million upfront. At the time, Lantheus hailed Evergre

-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome -- -- Pro-forma cash balance at the end of September 2026 was $293.6 million with anticipated cash runway through 2028 -- SAN DIEGO , Nov. 12, 2026 /PRNewswire/ -- / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a bioph

Briefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of December 31, 2026 Pivotal NEPHRO study currently exceeds 80% power for primary endpoint supporting a potential early close of enrollment Updated market research raises nafamostat peak sales estimate for CRRT above $200 million Cash and investments of $14.2 million at September 30, 2026 Conference call and webcast to be held on Thursday, Novembe

Sarasota, FL, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, today announced that NYSE Regulation has accepted the Company’s compliance plan (the “Plan”) and granted an extension through February 25, 2028 to regain compliance with NYSE American continued listing standards. The acceptance of the Company’s Plan enables Oragenics to maintain its NYSE American

.HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models (ESGCT 2026); Phase 1 IIT in China on track for initiation, with preliminary clinical data expected in H2 2027 .HEAL-201 achieved >90% reduction in plasma PCSK9 in a humanized liver mouse model; preliminary clinical data expected in H1 2028 Cash, cash equivalents and fixed-term deposits of $149 million as of September 30, 2026 1 ; realignment of the operatin